---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-043601"
form_type: "8-K"
ticker: "COCH"
cik: "0001840877"
company_name: "Envoy Medical, Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T23:32:16.835197+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Envoy Medical Q1 revenue $59K, down from $78K; draws $5M from $10M Glen Taylor loan

## Summary
- Revenue $59K for Q1 2024 vs $78K in Q1 2023; decrease due to fewer battery replacement requests.
- R&D expense increased $0.4M; G&A expense increased $0.7M; sales/marketing down $46K.
- Cash and cash equivalents $4.9M as of March 31, 2024.
- Entered $10M unsecured loan facility with Glen Taylor; initial draw $5M at 8% interest, five-year term.
- All three EFS participants at Mayo completed 12-month follow-up; plan to file IDE for Acclaim CI pivotal trial later in 2024.

## SEC filing metadata
- accession: 0001213900-24-043601
- form_type: 8-K
- ticker: COCH
- cik: 0001840877
- company_name: Envoy Medical, Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840877/000121390024043601/0001213900-24-043601-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840877/000121390024043601/ea0206113-8k_envoymed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-043601
- JSON: https://secwatch.observer/filing/0001213900-24-043601.json
- Plain text: https://secwatch.observer/filing/0001213900-24-043601.txt

## Key facts
- Earnings Releases
  Envoy Medical, Inc. reported first quarter ended March 31, 2024 results: revenue $59 thousand.
  - Period: first quarter ended March 31, 2024
  - Revenue: $59 thousand
  - Result: reported results
  source text: forward to the prospect of disrupting the hearing industry with new competition and significant innovation.” Financial Results for the Quarter Ended March 31, 2024 Revenue was $59 thousand compared to $78 thousand for the same period in 2023, the decrease is primarily due to a decrease in the number of battery replacement requests received during the three months
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840877/000121390024043601/0001213900-24-043601-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.